Cytomegalovirus Infection After Transplantation: a Study of New Markers to Optimize the Selection of Antiviral Therapies and Reduce the Risk of Developing Direct and Indirect Infection-related Complications
Key facts
- Who runs it
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- People taking part
- 330 people, planned
- Started
- Nov 2026
- Expected to end
- Jun 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- CMV-RNAemia
- CMV-DNAemia
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (5)Hide the full registry criteria
Who can take part
- CSE/SOT transplant patient
- Currently receiving antiviral medication
- Age ≥ 18 years
- Signed informed consent form for participation and data processing
Who cannot take part
- Localized CMV infection / organ disease
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Citomegalovirus infection
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Background and Rationale Cytomegalovirus (CMV) remains a major cause of morbidity and mortality in recipients of solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT). Current management relies on antiviral prophylaxis or pre-emptive therapy guided primarily by CMV-DNAemia monitoring. However, recently introduced antivirals such as letermovir and maribavir have changed the virological profile of CMV infection, highlighting limitations of DNAemia as a marker of active viral replication and increasing the need for improved resistance monitoring.
Read full original descriptionShow less
Preliminary studies suggest that CMV-RNAemia (UL21.5 mRNA) may be a more accurate marker of active viral replication and may detect viral clearance approximately 7-14 days earlier than CMV-DNAemia. In parallel, Next Generation Sequencing (NGS) may provide superior detection of antiviral resistance mutations, including low-frequency variants that cannot be identified by conventional Sanger sequencing.
Primary Objective To determine whether using CMV-RNAemia to guide discontinuation of antiviral therapy in transplant recipients can reduce treatment duration and drug-related toxicity without increasing the risk of CMV relapse, compared with the current standard based on CMV-DNAemia.
Secondary Objectives
Compare the diagnostic performance of NGS and Sanger sequencing in detecting CMV antiviral resistance mutations.
Estimate the incidence of resistant or refractory CMV infection (R/R-CMV) in transplant recipients.
Identify risk factors associated with the development of R/R-CMV according to transplant type.
Study Design This is a single-center, pragmatic, randomized controlled interventional study conducted at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.
Adult transplant recipients (≥18 years) with CMV infection requiring antiviral therapy will be randomized (1:1) into two groups:
Experimental arm: antiviral therapy discontinued after two consecutive negative CMV-RNAemia results.
Control arm: antiviral therapy discontinued after two consecutive negative CMV-DNAemia results.
Patients will be followed from treatment initiation, with virological monitoring continuing during therapy and follow-up.
Population and Sample Size The study plans to enroll approximately 330 CMV infection episodes, including an estimated 10% drop-out rate, with 150 participants per study arm plus additional cases to compensate for losses.
Endpoints Primary endpoints include:
Time to treatment discontinuation. Time to viral clearance. Incidence and timing of clinically significant CMV relapse. Antiviral drug toxicity.
Secondary endpoints include:
Sensitivity, specificity, and predictive value of NGS versus Sanger sequencing. Incidence of resistant/refractory CMV infection. Identification of clinical and virological risk factors for resistance.
Resistance Analysis In suspected resistant or refractory CMV infections, residual biological samples will undergo NGS analysis targeting CMV genes involved in antiviral resistance (UL97, UL54, UL56, UL89, UL27, UL51). Results will be compared with standard Sanger sequencing to assess earlier detection of resistance mutations and minor viral variants.
Expected Impact The study aims to establish CMV-RNAemia as a clinically useful marker for earlier identification of viral clearance, enabling shorter antiviral treatment and reduced toxicity. It also seeks to validate NGS-based resistance testing as a more sensitive tool for detecting emerging CMV drug resistance, ultimately supporting a more personalized approach to CMV management in transplant recipients and potentially other immunocompromised populations.
Study Duration and Funding The study is expected to last 24 months (18 months recruitment, 4 months follow-up, 2 months analysis) and is funded by the Italian Ministry of Health (Ricerca Corrente 2026, project RC-2026-2802099).
The 2 groups in the trial
- Antiviral therapy will be discontinued after two consecutive negative results for CMV-RNAemiaTreatment being tested
Treatment: CMV-RNAemia and CMV-DNAemia
- Antiviral therapy will be discontinued after two consecutive negative results for CMV-DNAemiaExisting treatment, for comparison
Treatment: CMV-DNAemia
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07945379, who can take part
- Record updated
- 18 November 2026